GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Customers are to be offered discounted weight loss treatments through insurance giant Vitality in a UK first. The group, ...

Sarah O’Keeffe recounts her fulfilling career path with Eli Lilly from employee to Senior Vice President, Product Research ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...